Category: Guest content

Patenting the Microbiome – Part 2: Microbiome IP Panel, 2017 BIO Convention

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.  Given the increasing focus on microbiome technologies for better, safer therapies, and critical importance of Intellectual Property (IP) protection for their full commercialization, it is great to see the 2017 […]




Click here for reuse options!
Copyright 2017 Biotechblog

Solving the problem of biologic delivery: Large volume wearable injectors

This is a guest post from Michael D. Hooven, President & CEO, Enable Injections Inc. The oxpecker perches on the backs of zebras and eats the ticks and parasites that live on their skin. The bird gets its food, and the beasts get pest control. It’s an example of mutualism at its best – both parties […]




Click here for reuse options!
Copyright 2017 Biotechblog

From PhD to Life

This is a guest post from Craig Stropkay. Craig is Director and Life Science Consultant at KOLgroups, LLC Reach for the stars, they said.  You should definitely go get your PhD, you’d be great for it, they said.  Well, I guess they did have a point.  Pursuing my doctorate degree in Molecular Biology at Brandeis was […]




Click here for reuse options!
Copyright 2017 Biotechblog

3 Tips for Finding the Right Talent for Your Biotech Startup

This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the last time you used a matchmaking service? Chances are it was today. Platforms like Amazon, Airbnb, eBay and Uber (as well as the proverbial dating sites) have transformed matchmaking into an everyday adventure in which […]




Click here for reuse options!
Copyright 2017 Biotechblog

A Brief Patent Primer

This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield Management, and Dr. Eng is Counsel at Hogan Lovells. … the very first official thing I did, in my administration … was to start a patent office; for I knew that a country without a […]




Click here for reuse options!
Copyright 2016 Biotechblog

Biotech in Countries Starting with “I” – Part 11: Italy (secondo)

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. The run-up to Christmas in Italy is a magical experience, and a great time to revisit Italian agricultural biotechnology. Readers of this irregular series may recall an earlier entry on […]




Click here for reuse options!
Copyright 2016 Biotechblog

Which drug makers do a good job getting poor patients access to their medicines?

The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries have access to its medicines. Yet the real picture is actually more nuanced, according to a newly released report that finds some – but not all – drug makers are making headway. Some companies, for […]





Addressing the Challenges of Pharmaceutical Distribution in International Markets

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. If domestic pharmaceutical distribution is complex, international distribution is considerably more complicated International growth markets for pharmaceuticals represent enormous opportunities, but they also bring their own unique challenges, including infrastructure, fragmented distribution, and a patchwork […]




Click here for reuse options!
Copyright 2016 Biotechblog

Addressing the Challenges of Pharmaceutical Distribution in the United States

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. Pharmaceutical distributors face significant supply chain challenges Designing, implementing, and managing efficient product distribution can present pharmaceutical distributors and wholesalers with opportunities to create a long term strategic advantage. Distribution of pharmaceuticals has always been […]




Click here for reuse options!
Copyright 2016 Biotechblog

Treat pharma as a utility, and 10 other ways states can lower drug prices

As prescription drug costs continue to squeeze state budgets, a group of state health policy makers is offering some novel – and also some familiar – suggestions for coping. These include regulating the pharmaceutical industry as a utility, allowing states to operate as pharmacy benefit managers and waiving some provisions of the Medicaid program. In […]





%d bloggers like this: